Migraine and Blood Vessels: A Study That Says “No” to a New Target

The research set out to see if blocking a certain type of ion channel—called HCN—in the body could stop migraines that are triggered by opening potassium channels in blood vessels. The study used a double‑blind, placebo‑controlled design with adults who suffer from migraines without aura. Each participant received a drug that opens the potassium channels and then, either an HCN blocker or a placebo. The main question was whether the HCN blocker would reduce the chance of getting a migraine within 12 hours. Results showed that the HCN blocker did not change migraine rates: 22 out of 27 people had migraines after both the active drug and the placebo. Headache intensity over time was also similar between groups, and blood pressure responses did not differ.

The researchers also tested the idea in mice, giving them the HCN blocker before or after inducing pain with the same potassium‑channel opener. The drug had no effect on the mice’s sensitivity to touch, a proxy for migraine pain. Together, the human and animal data suggest that HCN channels are not involved in turning vascular potassium‑channel activation into migraine pain. This points to other mechanisms at the interface between blood vessels and nerves as the key players in migraine initiation. The trial was registered under NCT04853797 and followed all ethical guidelines for both human participants and animal work.

Actions